Abstract

Background. The pathways of iron acquisition, outflow, storage and regulation are disrupted in cancer, which suggests that the reprogramming of iron metabolism is one of the central aspects of the survival of tumor cells.Aim. Is to review and generalize modern literature data on the regulation of hepcidin, ferroportin and prospects for the correction of iron metabolism in cancer patients.Materials and Methods. The paper presents the results of international and domestic studies of the peculiarities of iron metabolism and the prospects for its correction in cancer patients. The search for relevant sources was carried out in the web of Science, PubMed, Medline, eLibrary.ru systems for 1988–2023. Of the analyzed studies 61, the most relevant, were used to write a systematic review.Results. Over the past decade, a new understanding has emerged of the role of proteins, in particular hepcidin and ferroportin, which regulate cellular iron in cancer growth, angiogenesis and metastasis. New treatment methods with hepcidin-modifying strategies and stabilizers of hypoxia-induced factors are emerging, but their therapeutic efficacy for correcting iron metabolism in cancer patients needs to be evaluated and clinical trials.Conclusion. Analysis of the literature data has shown the high relevance of studies of the regulation of hepcidin and ferroportin in cancer patients and the need for further study of this problem.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call